Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC(2)-NY-ESO-1(M) + TRICOM
- Development stage
- Phase 2
- Lead developer
- Sanofi Pasteur
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ALVAC(2)-NY-ESO-1(M) + TRICOM is an investigational therapeutic cancer vaccine comprised of a recombinant canarypox virus vector (ALVAC(2)) encoding the tumor antigen NY-ESO-1(M) and TRICOM, a set of three human costimulatory molecules (B7-1/CD80, ICAM-1, and LFA-3). It is designed to induce both cellular and humoral immune responses against NY-ESO-1, a highly immunogenic cancer-testis antigen expressed in various malignancies. The addition of TRICOM aims to enhance T-cell activation and anti-tumor immune response. The vaccine is administered subcutaneously and has been studied primarily in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancers who express NY-ESO-1 or LAGE-1 and are in remission after standard therapy[1][2][3].
- Other names
- ALVAC(2)-NY-ESO-1(M)/TRICOMvCP2292vCP-2292vCP 2292
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)CD58 (Leukocyte function-associated antigen 3)CD80 (T-lymphocyte activation antigen CD80)ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on ALVAC(2)-NY-ESO-1(M) + TRICOM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC(2)-NY-ESO-1(M) + TRICOM.